Sun Pharma Advanced Research Company Limited
NSE: SPARC BSE: SPARC
NSE
126.08
1.10 (0.88%)
Prev Close
124.98
Open Price
128
Volume
7,990,822
Today Low / High
126.08 / 141.85
52 WK Low / High
109.3 / 204.4
Range
120 - 132
BSE
126.30
1.65 (1.32%)
Prev Close
126.3
Open Price
126.9
Volume
654,176
Today Low / High
126.3 / 141.95
52 WK Low / High
109.2 / 204.25
Range
120 - 133
The stock is currently trading on both the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE). On the NSE, the stock is priced at 126.08 (target range: 120 - 132), reflecting a change of 1.1 (0.88014%). On the BSE, it is listed at 126.3 (target range: 120 - 133), showing a change of 1.65 (1.3237%). Both the NSE and BSE data indicate positive movement, suggesting the stock is on an upward trend. This could be an attractive opportunity for investors looking for growth.
01 Feb
128.00
4.78%
30 Jan
124.85
0.99%
29 Jan
124.99
-0.01%
28 Jan
123.25
1.41%
27 Jan
125.49
-1.94%
23 Jan
129.40
-3.45%
22 Jan
129.19
0.28%
21 Jan
127.40
1.10%
20 Jan
130.29
-1.77%
19 Jan
133.00
-2.04%
16 Jan
136.01
-1.83%
14 Jan
136.79
-0.99%
13 Jan
136.26
-0.30%
12 Jan
135.00
0.19%
09 Jan
135.14
-2.04%
08 Jan
139.00
-2.78%
07 Jan
137.33
0.41%
06 Jan
135.39
0.38%
05 Jan
135.83
-0.36%
Sun Pharma Advanced Research Company Limited Graph
Sun Pharma Advanced Research Company Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges
If you are looking for the target price for Sun Pharma Advanced Research Company Limited T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 126.08, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.
| Scenario | Price | Target | Range |
|---|---|---|---|
| Bullish Scenario | 126.30 | 127.56 | 114.81 - 140.32 |
| 128.83 | 103.06 - 154.59 | ||
| 130.09 | 91.06 - 169.12 | ||
| Bearish Scenario | 126.30 | 125.04 | 112.53 - 137.54 |
| 123.77 | 99.02 - 148.53 | ||
| 122.51 | 85.76 - 159.26 |
Overview of Sun Pharma Advanced Research Company Limited
ISIN
INE232I01014
Industry
Drug Manufacturers - Specialty & Generic
Vol.Avg
4,644,192
Market Cap
40,915,681,815
Last Dividend
0
Official Website
IPO Date
2003-01-14
DCF Diff
175.55
DCF
-49
Financial Ratios Every Investor Needs
Annual Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 71.77 Cr | 23.12 Cr | 48.65 Cr | 0.6779 | 81.33 Cr | 91.72 Cr | -277.98 Cr | -342.51 Cr | -10.55 | -323.14 Cr | -4.7723 |
| 2024-03-31 | 75.55 Cr | 199.37 Cr | -123.82 Cr | -1.6391 | 479.34 Cr | 152.46 Cr | -411.50 Cr | -387.21 Cr | -11.93 | -373.15 Cr | -5.1256 |
| 2023-03-31 | 238.78 Cr | 171.58 Cr | 82.12 Cr | 0.3439 | 452.84 Cr | 131.95 Cr | -223.64 Cr | -222.58 Cr | -7.82 | -203.18 Cr | -0.9322 |
| 2022-03-31 | 137.25 Cr | 126.70 Cr | 10.55 Cr | 0.0769 | 324.00 Cr | 69.52 Cr | -196.91 Cr | -203.40 Cr | -7.73 | -179.90 Cr | -1.4819 |
| 2021-03-31 | 252.96 Cr | 206.40 Cr | 46.56 Cr | 0.1840 | 387.93 Cr | 51.93 Cr | -145.90 Cr | -151.14 Cr | -5.77 | -129.57 Cr | -0.5975 |
Annual Financials Balance Sheet
| Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 1.96 Cr | 335.53 Cr | 552.48 Cr | -216.9500 Cr | 268.92 Cr | 266.96 Cr | 0.00 Cr | 99.26 Cr | 0.00 Cr | 62.60 Cr | 25.64 Cr | 374.2400 Cr |
| 2024-03-31 | 5.33 Cr | 515.04 Cr | 389.29 Cr | 125.7554 Cr | 61.15 Cr | 55.82 Cr | 0.00 Cr | 108.62 Cr | 16.68 Cr | 103.49 Cr | 25.02 Cr | 265.0578 Cr |
| 2023-03-31 | 0.58 Cr | 830.12 Cr | 317.35 Cr | 512.7700 Cr | 15.67 Cr | 15.09 Cr | -4.17 Cr | 107.28 Cr | 18.22 Cr | 117.65 Cr | -228.64 Cr | 178.9400 Cr |
| 2022-03-31 | 1.22 Cr | 280.08 Cr | 248.86 Cr | 31.2257 Cr | 79.21 Cr | 77.99 Cr | 0.00 Cr | 95.12 Cr | 0.03 Cr | 66.85 Cr | 11.52 Cr | 171.4289 Cr |
| 2021-03-31 | 9.30 Cr | 229.69 Cr | 397.94 Cr | -168.2516 Cr | 236.38 Cr | 227.08 Cr | 3.32 Cr | 95.11 Cr | 9.80 Cr | 39.24 Cr | 0.00 Cr | 233.3517 Cr |
Annual Financials Cash Flow Statement
| Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | -360.2900 Cr | 157.6600 Cr | 199.2500 Cr | -370.6300 Cr | -3.3695 Cr | 1.9600 Cr | -10.3400 Cr | -342.5100 Cr | 211.1853 Cr | 0.0000 Cr | 0.0000 Cr |
| 2024-03-31 | -429.1883 Cr | 391.5271 Cr | 42.4051 Cr | -455.6962 Cr | 4.7459 Cr | 5.3295 Cr | -26.5079 Cr | -387.2139 Cr | 46.9490 Cr | 0.0000 Cr | 0.0000 Cr |
| 2023-03-31 | -69.1200 Cr | -548.2800 Cr | 616.7600 Cr | -84.5100 Cr | -0.6400 Cr | 0.5800 Cr | -15.3900 Cr | -222.5800 Cr | -74.9490 Cr | 0.0000 Cr | 0.0019 Cr |
| 2022-03-31 | -208.2325 Cr | -29.1670 Cr | 229.3209 Cr | -240.9104 Cr | -8.0803 Cr | 1.2242 Cr | -32.6779 Cr | -203.3954 Cr | -155.5452 Cr | 0.0000 Cr | 0.0000 Cr |
| 2021-03-31 | -151.8956 Cr | 1.5618 Cr | 159.2843 Cr | -157.8907 Cr | 8.9522 Cr | 9.3045 Cr | -5.9951 Cr | -151.1388 Cr | 169.4405 Cr | 0.0000 Cr | 0.0000 Cr |
Quarterly Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|
| 2025-09-30 | 7.86 Cr | 14.11 Cr | -6.25 Cr | -0.7952 | -68.28 Cr | -75.85 Cr | -2.34 | -65.71 Cr | -9.6501 |
| 2025-06-30 | 9.64 Cr | 10.67 Cr | -1.03 Cr | -0.1068 | -54.76 Cr | -51.87 Cr | -1.60 | -42.94 Cr | -5.3807 |
| 2025-03-31 | 27.19 Cr | 5.70 Cr | 21.49 Cr | 0.7904 | -56.13 Cr | -59.77 Cr | -1.84 | -53.03 Cr | -2.1982 |
| 2024-12-31 | 14.91 Cr | 30.36 Cr | -15.45 Cr | -1.0362 | -76.83 Cr | -79.51 Cr | -2.45 | -73.50 Cr | -5.3327 |
| 2024-09-30 | 12.86 Cr | -74.87 Cr | 87.73 Cr | 6.8219 | -106.07 Cr | -107.33 Cr | -3.31 | -102.87 Cr | -8.3460 |
Quarterly Financials Balance Sheet
| Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities |
|---|---|---|---|---|---|---|---|---|---|
| 2025-09-30 | 0.94 Cr | 2.06 Cr | 3.00 Cr | 6.06 Cr | 0.00 Cr | 14.49 Cr | 91.48 Cr | 322.44 Cr | 667.08 Cr |
| 2025-06-30 | 0.00 Cr | 0.00 Cr | 1.96 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 216.95 Cr |
| 2025-03-31 | 1.96 Cr | 0.00 Cr | 1.96 Cr | 16.06 Cr | 0.00 Cr | 26.19 Cr | 99.26 Cr | 335.53 Cr | 552.48 Cr |
| 2024-12-31 | 0.00 Cr | 0.00 Cr | 6.07 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 77.38 Cr |
| 2024-09-30 | 5.67 Cr | 0.40 Cr | 6.07 Cr | 13.61 Cr | 0.00 Cr | 90.55 Cr | 104.65 Cr | 320.81 Cr | 398.19 Cr |
Quarterly Financials Cash Flow Statement
| Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|
| 2025-06-30 | -51.87 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2025-03-31 | -59.77 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-12-31 | -79.51 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-09-30 | -107.33 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-06-30 | -95.90 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
Splits History
| Date | Label | Split Ratio |
|---|---|---|
| 2012-08-23 | August 23, 12 | 127:125 |
Similar Stocks: Drug Manufacturers - Specialty & Generic
| Company Name | Symbol | Price | Market Cap | Volume |
|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | SUNPHARMA | ₹1,595.30 | ₹3,827,659,077,641.00 | ₹1,849,710.00 |
| Divi's Laboratories Limited | DIVISLAB | ₹6,031.00 | ₹1,601,041,005,980.00 | ₹96,030.00 |
| Torrent Pharmaceuticals Limited | TORNTPHARM | ₹3,960.80 | ₹1,340,514,698,752.00 | ₹50,076.00 |
| Dr. Reddy's Laboratories Limited | DRREDDY | ₹1,200.00 | ₹999,081,828,000.00 | ₹380,220.00 |
| Lupin Limited | LUPIN | ₹2,152.80 | ₹983,396,887,200.00 | ₹153,290.00 |
| Zydus Lifesciences Limited | ZYDUSLIFE | ₹885.30 | ₹890,818,951,347.00 | ₹140,316.00 |
| Mankind Pharma Limited | MANKIND | ₹2,124.00 | ₹876,797,972,928.00 | ₹287,261.00 |
| Aurobindo Pharma Limited | AUROPHARMA | ₹1,182.80 | ₹686,972,159,684.00 | ₹574,635.00 |
| Alkem Laboratories Limited | ALKEM | ₹5,620.00 | ₹671,955,300,000.00 | ₹20,830.00 |
| Glenmark Pharmaceuticals Limited | GLENMARK | ₹1,960.90 | ₹553,367,566,368.00 | ₹308,665.00 |
| Laurus Labs Limited | LAURUSLABS | ₹940.90 | ₹507,951,058,004.00 | ₹1,196,464.00 |
| Suven Pharmaceuticals Limited | SUVENPHAR | ₹1,078.00 | ₹412,407,234,624.00 | ₹1,177,218.00 |
| Ipca Laboratories Limited | IPCALAB | ₹1,427.70 | ₹362,213,512,039.00 | ₹38,416.00 |
| Ajanta Pharma Limited | AJANTPHARM | ₹2,782.00 | ₹347,570,905,968.00 | ₹27,274.00 |
| J. B. Chemicals & Pharmaceuticals Limited | JBCHEPHARM | ₹1,880.70 | ₹301,730,104,500.00 | ₹48,837.00 |
| Emcure Pharmaceuticals Ltd. | EMCURE | ₹1,485.00 | ₹281,515,221,900.00 | ₹56,011.00 |
| Piramal Enterprises Limited | PEL | ₹1,124.20 | ₹254,856,250,172.00 | ₹2,148,582.00 |
| Wockhardt Limited | WOCKPHARMA | ₹1,382.20 | ₹224,596,675,992.00 | ₹241,327.00 |
| AstraZeneca Pharma India Limited | ASTRAZEN | ₹8,615.00 | ₹215,375,000,000.00 | ₹3,296.00 |
| Eris Lifesciences Limited | ERIS | ₹1,386.10 | ₹188,810,232,615.00 | ₹11,485.00 |
| Neuland Laboratories Limited | NEULANDLAB | ₹13,251.00 | ₹170,008,859,139.00 | ₹53,893.00 |
| Alembic Pharmaceuticals Limited | APLLTD | ₹777.60 | ₹152,847,485,222.00 | ₹26,375.00 |
| Jubilant Pharmova Limited | JUBLPHARMA | ₹953.75 | ₹151,045,147,155.00 | ₹22,670.00 |
| NATCO Pharma Limited | NATCOPHARM | ₹835.90 | ₹149,717,940,333.00 | ₹208,764.00 |
| Cohance Lifesciences Limited | COHANCE | ₹367.50 | ₹140,593,423,950.00 | ₹169,039.00 |
| Caplin Point Laboratories Limited | CAPLIPOINT | ₹1,802.10 | ₹136,980,677,362.00 | ₹25,851.00 |
| Granules India Limited | GRANULES | ₹557.20 | ₹135,215,008,555.00 | ₹273,857.00 |
| Glenmark Life Sciences Limited | GLS | ₹1,086.00 | ₹133,070,838,000.00 | ₹130,938.00 |
| Alivus Life Sciences Ltd. | ALIVUS | ₹937.60 | ₹115,025,705,600.00 | ₹28,984.00 |
| Viyash Scientific Limited | VIYASH | ₹203.61 | ₹88,815,813,868.00 | ₹245,657.00 |
| Procter & Gamble Health Limited | PGHL | ₹5,303.00 | ₹88,026,522,746.00 | ₹4,739.00 |
| Strides Pharma Science Limited | STAR | ₹877.00 | ₹80,835,470,178.00 | ₹379,638.00 |
| Aarti Pharmalabs Limited | AARTIPHARM | ₹756.05 | ₹68,533,886,629.00 | ₹69,500.00 |
| Akums Drugs & Pharmaceuticals Ltd. | AKUMS | ₹446.00 | ₹68,283,517,868.00 | ₹92,422.00 |
| FDC Limited | FDC | ₹376.70 | ₹61,330,558,643.00 | ₹31,298.00 |
| Shilpa Medicare Limited | SHILPAMED | ₹288.95 | ₹56,513,365,733.00 | ₹4,776,413.00 |
| Sequent Scientific Limited | SEQUENT | ₹202.40 | ₹50,564,340,966.00 | ₹13,647.00 |
| Sun Pharma Advanced Research Company Limited | SPARC | ₹126.08 | ₹40,915,681,815.00 | ₹7,990,855.00 |
| Innova Captab Limited | INNOVACAP | ₹695.00 | ₹39,771,325,655.00 | ₹12,945.00 |
| Gujarat Themis Biosyn Ltd. | GUJTHEM | ₹326.85 | ₹35,615,296,865.00 | ₹58,760.00 |
| Aarti Drugs Limited | AARTIDRUGS | ₹386.75 | ₹35,298,672,500.00 | ₹63,468.00 |
| Orchid Pharma Limited | ORCHPHARMA | ₹693.00 | ₹35,148,339,765.00 | ₹14,366.00 |
| RPG Life Sciences Limited | RPGLIFE | ₹2,007.90 | ₹33,208,688,219.00 | ₹3,827.00 |
| Gufic Biosciences Limited | GUFICBIO | ₹303.90 | ₹30,475,853,573.00 | ₹29,080.00 |
| Suven Life Sciences Limited | SUVEN | ₹132.81 | ₹30,210,821,940.00 | ₹346,948.00 |
Key Executives
Chief Operating Officer
Nitin Dharmadhikari
Gender: Not Specified
Year Born: 1962
Executive Vice President of Biologics & Chief Innovation Officer
Nitin K. Damle
Gender: Not Specified
Year Born:
Head of Drug Discovery & Preclinical Development
Vikram Ramanathan
Gender: male
Year Born:
Head of Drug Delivery Systems
Yashoraj Zala
Gender: male
Year Born:
Chief Executive Officer
Anilkumar Raghavan
Gender: male
Year Born: 1968
Chief Financial Officer
Anup Rathi
Gender: male
Year Born:
Senior General Manager of Business Development, Corporate Communication & Investor Relations
Jaydeep Issrani
Gender: male
Year Born:
Head Clinical Development
Siu-Long Yao
Gender: male
Year Born:
Company Secretary & Compliance Officer
Kajal Damania
Gender: female
Year Born:
Chief Human Resource Officer
Shanta Gupta
Gender: female
Year Born:
FAQs about Sun Pharma Advanced Research Company Limited
Who is the CEO of the company?
The CEO is Anilkumar Raghavan.
What is the current market price of the stock?
The current price is ₹126.08.
What is the 52-week price range?
The range is ₹109.3-204.4.
What is the market capitalization of the company?
The market capitalization is ₹4,091.57 crores.
What is the Price-to-Earnings (P/E) ratio?
The P/E ratio is -15.31.
Which sector does the company belong to?
The company operates in the Healthcare sector.
What does the company do?
Overview of Sun Pharma Advanced Research Company Limited (ISIN: INE232I01014) is a leading Drug Manufacturers - Specialty & Generic in India. With a market capitalization of ₹4,091.57 crores and an average daily volume of 4,644,192 shares, it operates in the Drug Manufacturers - Specialty & Generic. The company last declared a dividend of ₹0.